LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Better-than-expected Medicare Advantage membership aids HUM's third-quarter results.
Humana Inc. (NYSE:HUM ) Q3 2024 Earnings Conference Call October 30, 2024 9:00 AM ET Company Participants Lisa Stoner - VP, IR James Rechtin - President and CEO Susan Diamond - CFO George Renaudin - President, Insurance Conference Call Participants Justin Lake - Wolfe Research Ann Hynes - Mizuho Andrew Mok - Barclays Ben Hendrix - RBC Capital Markets Sarah James - Cantor Fitzgerald Joshua Raskin - Nephron Research Stephen Baxter - Wells Fargo Joanna Gajuk - Bank of America George Hill - Deutsche Bank Whit Mayo - Leerink Partners A.J. Rice - UBS David Windley - Jefferies Michael Ho - Baird Operator Good day and thank you for standing by.
Humana (NYSE:HUM), a for-profit American health insurance firm, reported a beat on the top and bottom lines for the third quarter and strengthened its full year profit guidance, sending its shares higher on Wednesday. Revenue for Q3 was $29.3 billion, topping estimates of $28.7 billion.
While the top- and bottom-line numbers for Humana (HUM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Humana (HUM) came out with quarterly earnings of $4.16 per share, beating the Zacks Consensus Estimate of $3.48 per share. This compares to earnings of $7.78 per share a year ago.
The health insurer still sees full-year adjusted per-share earnings of at least $16.
Humana beat Wall Street estimates for third-quarter profit on Wednesday, helped by strength in its government-backed Medicare Advantage insurance business for older adults.
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
The health insurer's third-quarter report comes Wednesday. The numbers will show the growing problems with Medicare Advantage.